Sinopharm Group (1099) Stock Overview
Engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
1099 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Sinopharm Group Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$19.14 |
| 52 Week High | HK$23.65 |
| 52 Week Low | HK$16.02 |
| Beta | 0.58 |
| 1 Month Change | -0.31% |
| 3 Month Change | 6.57% |
| 1 Year Change | -2.35% |
| 3 Year Change | 2.46% |
| 5 Year Change | 5.98% |
| Change since IPO | 3.35% |
Recent News & Updates
There Are Reasons To Feel Uneasy About Sinopharm Group's (HKG:1099) Returns On Capital
Jul 03
There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
May 27We Think You Can Look Beyond Sinopharm Group's (HKG:1099) Lackluster Earnings
May 06Recent updates
There Are Reasons To Feel Uneasy About Sinopharm Group's (HKG:1099) Returns On Capital
Jul 03There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
May 27We Think You Can Look Beyond Sinopharm Group's (HKG:1099) Lackluster Earnings
May 06Earnings Miss: Sinopharm Group Co. Ltd. Missed EPS By 12% And Analysts Are Revising Their Forecasts
Mar 26Sinopharm Group (HKG:1099) Is Reinvesting At Lower Rates Of Return
Mar 19Sinopharm Group Co. Ltd.'s (HKG:1099) Share Price Is Matching Sentiment Around Its Earnings
Feb 25Sinopharm Group (HKG:1099) Has A Pretty Healthy Balance Sheet
Dec 30At HK$20.45, Is It Time To Put Sinopharm Group Co. Ltd. (HKG:1099) On Your Watch List?
Nov 26Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Shareholder Returns
| 1099 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 3.3% | 2.0% | 1.0% |
| 1Y | -2.3% | -20.2% | 27.8% |
Return vs Industry: 1099 exceeded the Hong Kong Healthcare industry which returned -20.2% over the past year.
Return vs Market: 1099 underperformed the Hong Kong Market which returned 27.8% over the past year.
Price Volatility
| 1099 volatility | |
|---|---|
| 1099 Average Weekly Movement | 2.9% |
| Healthcare Industry Average Movement | 6.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 1099 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1099's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 108,217 | Wanyong Lian | www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
Sinopharm Group Co. Ltd. Fundamentals Summary
| 1099 fundamental statistics | |
|---|---|
| Market cap | HK$59.73b |
| Earnings (TTM) | HK$7.76b |
| Revenue (TTM) | HK$633.98b |
Is 1099 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1099 income statement (TTM) | |
|---|---|
| Revenue | CN¥578.90b |
| Cost of Revenue | CN¥535.34b |
| Gross Profit | CN¥43.56b |
| Other Expenses | CN¥36.48b |
| Earnings | CN¥7.09b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.27 |
| Gross Margin | 7.53% |
| Net Profit Margin | 1.22% |
| Debt/Equity Ratio | 58.6% |
How did 1099 perform over the long term?
See historical performance and comparisonDividends
Does 1099 pay a reliable dividends?
See 1099 dividend history and benchmarks| Sinopharm Group dividend dates | |
|---|---|
| Ex Dividend Date | Jun 16 2025 |
| Dividend Pay Date | Aug 12 2025 |
| Days until Ex dividend | 29 days |
| Days until Dividend pay date | 28 days |
Does 1099 pay a reliable dividends?
See 1099 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/14 01:06 |
| End of Day Share Price | 2025/07/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinopharm Group Co. Ltd. is covered by 44 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Mann | Barclays |
| Derrick Sun | BNP Paribas Securities (Asia) |
| Bo Li | BofA Global Research |